Literature DB >> 11418871

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients.

C A Dykewicz1.   

Abstract

This article contains highlights of "Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients: Recommendations of the CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation," which was published in the Morbidity and Mortality Weekly Report. There are sections on the prevention of bacterial, viral, fungal, protozoal, and helminth infections and on hospital infection control, strategies for safe living following transplantation, immunizations, and hematopoietic stem cell safety. The guidelines are evidence-based, and prevention strategies are rated by both the strength of the recommendation and the quality of evidence that supports it. Recommendations are given for preventing cytomegalovirus disease with prophylactic or preemptive gancyclovir, herpes simplex virus disease with prophylactic acyclovir, candidiasis with fluconazole, and Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients.

Entities:  

Mesh:

Year:  2001        PMID: 11418871     DOI: 10.1086/321805

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  73 in total

Review 1.  Adjuvant treatment for pancreatic ductal carcinoma.

Authors:  T Macarulla; T Fernández; M E Gallardo; O Hernando; A M López; M Hidalgo
Journal:  Clin Transl Oncol       Date:  2017-06-21       Impact factor: 3.405

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 3.  Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Authors:  Cesare Gridelli; Andrea Ardizzoni; Massimo Barberis; Federico Cappuzzo; Francesca Casaluce; Romano Danesi; Giancarlo Troncone; Filippo De Marinis
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 4.  Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections.

Authors:  Michael D Duncan; David S Wilkes
Journal:  Proc Am Thorac Soc       Date:  2005

Review 5.  Biomarkers in pancreatic ductal adenocarcinoma.

Authors:  J Gallego; C López; R Pazo-Cid; F López-Ríos; A Carrato
Journal:  Clin Transl Oncol       Date:  2017-06-14       Impact factor: 3.405

Review 6.  Supportive care in pancreatic ductal adenocarcinoma.

Authors:  B Laquente; A Calsina-Berna; A Carmona-Bayonas; P Jiménez-Fonseca; I Peiró; A Carrato
Journal:  Clin Transl Oncol       Date:  2017-06-13       Impact factor: 3.405

7.  ABC4 Consensus: Assessment by a German Group of Experts.

Authors:  Nadia Harbeck; Diana Lüftner; Norbert Marschner; Michael Untch; Doris Augustin; Susanne Briest; Johannes Ettl; Renate Haidinger; Lothar Müller; Volkmar Müller; Eugen Ruckhäberle; Rachel Wuerstlein; Christoph Thomssen
Journal:  Breast Care (Basel)       Date:  2018-02-15       Impact factor: 2.860

Review 8.  Management of unresectable, locally advanced pancreatic adenocarcinoma.

Authors:  M Salgado; S Arévalo; O Hernando; A Martínez; R Yaya; M Hidalgo
Journal:  Clin Transl Oncol       Date:  2017-06-13       Impact factor: 3.405

9.  Pneumocystis jerovecii pneumonia in a patient with untreated chronic lymphocytic leukaemia: a novel case and postulations concerning the mechanism.

Authors:  Alexandros Kalkanis; Marc A Judson; Mark B Napier
Journal:  BMJ Case Rep       Date:  2013-11-28

Review 10.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.